Surgical Robotics Technology
SciBase Holding AB has announced that it is working with Mayo Clinic on pigmented lesion digital workflows with AI-driven Nevisense – the only FDA Approved device for skin cancer detection at point of care.
“Melanoma is the deadliest form of skin cancer and accounts for the majority of skin cancer deaths because it can spread from the skin to other parts of the body where it becomes difficult to treat and can be fatal. However, if caught early, melanoma is almost 100% curable. For these reasons, we are looking forward to understanding how the Nevisense technology can help clinicians in the early detection of melanoma,” said Alexander Meves, M.D., M.B.A, Professor of Dermatology, Mayo Clinic College of Medicine and Sciences.
“We are proud to work with the Mayo Clinic and believe this pilot represents an opportunity for SciBase to continue to address an unmet medical need by expanding access of the Nevisense test to more US patients at-point-of-care, when it is critical and makes a profound impact on patient care,” said Pia Renaudin, CEO of SciBase.
Source: SciBase Holding AB
